BerGenBio

AGM Information • May 31, 2019

BerGenBio ASA: Invitation to ASCO Update Call

BerGenBio ASA: Invitation to ASCO Update Call

Bergen, Norway, 31 May 2019 - BerGenBio ASA (OSE:BGBIO), will share its latest

updates and data on an investor call on 4 June 2019, during the annual American

Society of Clinical Oncology (ASCO) meeting. BerGenBio's senior management team

will be hosting the call at 15:30 CET.

Dial-in details are:

· Standard International Dial-In: +44 (0) 2071 928000

· United States Dial-In: 16315107495

· Participant Code: 4352428

The call will focus on two peer reviewed abstracts on Phase II clinical data

with bemcentinib in the treatment of Non-Small Cell Lung Cancer and Acute

Myeloid Leukemia.

A presentation will be available at www.bergenbio.com in the section

Investors/Presentations.

-Ends-

Contacts

Richard Godfrey CEO, BerGenBio ASA

+47 917 86 304

Rune Skeie, CFO, BerGenBio ASA

rune.skeie@bergenbio.com

+47 917 86 513

International Media Relations

Mary-Jane Elliott, Chris Welsh, Jessica Hodgson, Nicholas Brown, Carina Jurs,

Consilium Strategic Communications

bergenbio@consilium-comms.com

+44 20 3709 5700

Media Relations in Norway

Jan Petter Stiff, Crux Advisers

stiff@crux.no

+47 995 13 891

About BerGenBio

BerGenBio is a clinical-stage biopharmaceutical company focused on developing

transformative drugs targeting AXL as a potential cornerstone of therapy for

aggressive diseases, including immune-evasive, therapy resistant cancers. The

company's proprietary lead candidate, bemcentinib, is a potentially first-in

-class selective AXL inhibitor in a broad Phase II oncology clinical development

programme focussed on combination and single agent therapy in lung cancer and

leukaemia. A first-in-class functional blocking anti-AXL antibody is undergoing

Phase I clinical testing. In parallel, BerGenBio is developing a companion

diagnostic test to identify those patient populations most likely to benefit

from bemcentinib: this is expected to facilitate more efficient registration

trials supporting a precision medicine-based commercialisation strategy.

BerGenBio is based in Bergen, Norway with a subsidiary in Oxford, UK. The

company is listed on the Oslo Stock Exchange (ticker: BGBIO). For more

information, visit www.bergenbio.com

Forward looking statements

This announcement may contain forward-looking statements, which as such are not

historical facts, but are based upon various assumptions, many of which are

based, in turn, upon further assumptions. These assumptions are inherently

subject to significant known and unknown risks, uncertainties and other

important factors. Such risks, uncertainties, contingencies and other important

factors could cause actual events to differ materially from the expectations

expressed or implied in this announcement by such forward-looking statements.